{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:03:21Z","timestamp":1787666601217,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Oncology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1097\/01.cco.0000147383.04709.10","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T04:01:22Z","timestamp":1103169682000},"page":"55-60","source":"Crossref","is-referenced-by-count":147,"title":["DNA methylation and cancer therapy: new developments and expectations"],"prefix":"10.1097","volume":"17","author":[{"given":"Manel","family":"Esteller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.cco.0000147383.04709.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:33:30Z","timestamp":1785850410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200501000-00012"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1097\/01.cco.0000147383.04709.10","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}